Reduced exposure to calcineurin inhibitors in renal transplantation [8]

New England Journal of Medicine

Volumn 358, Issue 23, 2008, Pages 2518-2519

  Krüger, Bernd ^a   Banas, Miriam ^b   Hoffmann, Ute ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; DRUG METABOLITE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE; TACROLIMUS; CALCINEURIN; DACLIZUMAB; DRUG DERIVATIVE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; PREDNISONE; PROTEIN KINASE; RAPAMYCIN;

COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG EXPOSURE; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LETTER; LOADING DRUG DOSE; PRIORITY JOURNAL; DRUG COMBINATION; NOTE; PHARMACOKINETICS;

ANTIBODIES, MONOCLONAL; CALCINEURIN; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; PREDNISONE; PROTEIN KINASES; SIROLIMUS; TACROLIMUS; THERAPEUTIC EQUIVALENCY;

EID: 44849115944     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc080067     Document Type: Letter

References (2)

1. Hesselink DA, van Hest RM, Mathot RAA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. Am J Transplant 2005;5:987-94.
2. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 2003;75:Suppl:SS3-SS24.